All In Biotech

Drug Trial Radar · NCT03606408

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat

Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

127

Actual

Start

Oct 5, 2018

Primary completion

Nov 16, 2023

Study completion Nov 16, 2023

Sponsor

Lead sponsor
RECORDATI GROUPIndustry
Sponsor type
Industry
First posted
Jul 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.

Conditions

  • Cushing's Syndrome

Interventions

  • osilodrostatDrug

    osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse/Serious Adverse EventsTime frame: up to 5 years

Locations

56 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Colorado

    Aurora, Colorado

  • Emory University School of Medicine G2304 - C2301

    Atlanta, Georgia

  • Northwestern University SC - LCI699C2301

    Chicago, Illinois

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Columbia University Medical Center New York Presbyterian Neuroendocrine Unit

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pennsylvania Medical Center Univ Penn

    Philadelphia, Pennsylvania

  • Medical College of Wisconsin MCW 2

    Milwaukee, Wisconsin

  • Sanatorio Guemes

    CABA, Buenos Aires, Argentina

  • Universitaetsklinik fuer Innere Medizin III

    Vienna, Austria

  • Gasthuisberg University Hospital

    Leuven, Belgium

  • Universidade Federal do Ceara

    Fortaleza, Ceará, Brazil

  • Hospital Universitario Clementino Fraga Filho

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital do Servidor Publico Estadual de Sao Paulo

    São Paulo, São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da USP

    São Paulo, São Paulo, Brazil

  • USHATE Akad Ivan Penchev

    Sofia, Bulgaria

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Centre de recherche du CHUM CRCHUM

    Montreal, Quebec, Canada

  • CHUS Hopital Fleurimont

    Sherbrooke, Quebec, Canada

  • Peking University First Hospital

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • The First Affiliated Hopsital, Sun Yat-Sun University

    Guangzhou, Guangdong, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Clinica Los Yoses

    San Pedro, San Jose, Costa Rica, Costa Rica

  • Hopital Kremlin Bicetre

    Le Kremlin-Bicêtre, France

  • CHRU de Lille

    Lille, France

  • Hopital Cochin

    Paris, France

  • CHU de Bordeaux

    Pessac, Cedex, France

  • Universitaetsklinikum Erlangen Nuernberg

    Erlangen, Germany

  • Universitaetsklinikum Muenchen LMU

    München, Germany

  • All India Institute of Medical Sciences

    New Delhi, India

  • A O Universitaria Policlinico Federico II Univ Studi Fed II

    Naples, Italy

  • AOU Osp Riuniti Umberto I GM Lancisi G Salesi Univ Studi

    Ancona, AN, Italy

  • Azienda Ospedaliera di Padova Università degli Studi

    Padova, PD, Italy

  • Az Ospedaliero Universitaria Pisana Pres Osped di Cisanello

    Pisa, PI, Italy

  • National Hospital Organization Nagoya Medical Center

    Nagoya, Aichi-ken, Japan

  • Hyogo College of Medicine Hospital

    Nishinomiya, Hyōgo, Japan

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.